UBS Group’s Blueprint Medicines BPMC Stock Holding History

UBS Group’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-15,000	Closed	-$1.38M	–	9337
2023 Q4	$1.38M	Hold	15,000	–	–	﹤0.01%	4197
2023 Q3	$753K	Hold	15,000	–	–	﹤0.01%	4337
2023 Q2	$948K	Hold	15,000	–	–	﹤0.01%	4303
2023 Q1	$675K	Buy	+15,000	New	+$676K	﹤0.01%	4460

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $4.82B AUM 20.19% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's BPMC Position: Q3 2025 in Review

UBS Group sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 2,167,028 shares — an estimated $278M sold.

UBS Group first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $278M in Q2 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

UBS Group reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
UBS Group sold 2,167,028 Blueprint Medicines shares in Q3 2025, an estimated $278M.
UBS Group first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
UBS Group's Blueprint Medicines position peaked at $278M in Q2 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.